title: [Antibiotic resistance of Helicobacter pylori in an infectious disease referral center].
abstract: OBJECTIVE
  To estimate the frequency of H. pylori clinical isolates resistant to six commonly used antimicrobials.
  
  
  METHODS
  Cross-sectional observational study.
  
  
  METHODS
  A tertiary-referral health care institution in Mexico City.
  
  
  METHODS
  31 isolates of H. pylori from 31 patients with chronic antral gastritis were obtained from gastric mucosal biopsy specimens.
  
  
  METHODS
  The Minimum Inhibitory Concentration (MIC) to ampicillin, amoxycillin, tetracycline, doxycycline, metronidazole and to colloidal bismuth subcitrate was determined by the agar plate dilution test.
  
  
  RESULTS
  All isolates showed to be susceptible to the former four antibiotics but only in 46% and 55% growth was inhibited by 8 micrograms/mL and 16 micrograms/mL of metronidazole, respectively. All isolates were inhibited by < or = 128 micrograms/mL of bismuth. A 50% increase in the percentage of metronidazole-resistant isolates (MIC > or = 8 micrograms/mL) between 1988 to 1992 was observed.
  
  
  CONCLUSIONS
  There is a need of future studies in our setting aimed at assessing the cost/effectiveness of diverse H. pylori-associated peptic ulcer treatment options.
authors.affiliation: Departamento de Microbiología, Facultad de Medicina, U.N.A.M., México, D.F.
authors.forename: Y
authors.initials: Y
authors.lastname: López-Vidal
authors.forename: M
authors.initials: M
authors.lastname: Sigfrido Rangel-Frausto
authors.forename: J J
authors.initials: JJ
authors.lastname: Calva
mesh_terms: D000658:Amoxicillin / Q000494:pharmacology / Q000627:therapeutic use; D000667:Ampicillin / Q000494:pharmacology / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D005756:Gastritis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006782:Hospitals, Special / Q000706:statistics & numerical data; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D013752:Tetracycline / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D009942:Organometallic Compounds; D008795:Metronidazole; D000667:Ampicillin; D000658:Amoxicillin; D013752:Tetracycline; C002791:bismuth tripotassium dicitrate; D004318:Doxycycline
vernacular_title: Resistencia a antimicrobianos de Helicobacter pylori en un centro de referencia infectológico.